TMO:NYE-Thermo Fisher Scientific Inc (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 573.6

Change

0.00 (0.00)%

Market Cap

USD 56.05B

Volume

1.44M

Analyst Target

USD 451.22
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Thermo Fisher Scientific Inc offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

N/A

USD 186.23B
A Agilent Technologies Inc

N/A

USD 43.89B
IQV IQVIA Holdings Inc

N/A

USD 42.75B
MTD Mettler-Toledo International I..

N/A

USD 26.69B
WAT Waters Corporation

N/A

USD 19.21B
LH Laboratory Corporation of Amer..

N/A

USD 17.09B
DGX Quest Diagnostics Incorporated

N/A

USD 14.27B
RVTY Revvity Inc.

N/A

USD 12.54B
CRL Charles River Laboratories

N/A

USD 11.85B
QGEN Qiagen NV

N/A

USD 9.22B

ETFs Containing TMO

XDNA 9.55 % 0.00 %

N/A

N/A
SYNB Putnam Biorevolution ETF 7.30 % 0.00 %

N/A

USD 5.43M
LIFE-B:CA Evolve Global Healthcare .. 5.19 % 0.00 %

N/A

CAD 0.01B
XGES:LSE Xtrackers MSCI Genomic He.. 4.73 % 0.00 %

N/A

USD 3.48M
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.60 % 0.00 %

N/A

USD 3.48M
DXSI:XETRA Xtrackers - Stoxx Europe .. 4.55 % 0.00 %

N/A

USD 0.02B
AILG 4.51 % 0.00 %

N/A

N/A
IHCU:LSE iShares S&P 500 Health Ca.. 4.26 % 0.00 %

N/A

USD 1.69B
ZPDH:F SPDR S&P U.S. Health Care.. 4.24 % 0.00 %

N/A

USD 0.40B
ZPDH:XETRA SPDR S&P U.S. Health Care.. 4.24 % 0.00 %

N/A

USD 0.40B
GXLV:LSE SPDR® S&P® U.S. Health .. 4.24 % 0.00 %

N/A

USD 0.38B
IUHC:LSE iShares S&P 500 USD Healt.. 4.21 % 0.00 %

N/A

USD 2.22B
QDVG:F iShares S&P 500 Health Ca.. 4.21 % 0.00 %

N/A

USD 2.09B
QDVG:XETRA iShares S&P 500 Health Ca.. 4.21 % 0.00 %

N/A

USD 2.05B
XUHC:F Xtrackers (IE) Public Lim.. 4.16 % 0.00 %

N/A

USD 0.85B
XUHC:XETRA Xtrackers MSCI USA Health.. 4.16 % 0.00 %

N/A

USD 0.85B
XSHC:LSE Xtrackers MSCI USA Health.. 4.11 % 0.00 %

N/A

USD 0.80B
XUHC:LSE Xtrackers MSCI USA Health.. 4.11 % 0.00 %

N/A

USD 0.80B
IUHC:SW iShares S&P 500 Health Ca.. 4.10 % 0.00 %

N/A

USD 2.20B
SXLV:SW SPDR S&P U.S. Health Care.. 4.10 % 0.00 %

N/A

N/A
MHCD:CA Middlefield Healthcare Di.. 4.05 % 0.00 %

N/A

CAD 0.16B
XUHC:SW Xtrackers MSCI USA Health.. 3.98 % 0.00 %

N/A

USD 0.13M
WH2E:XETRA Invesco Markets II plc - .. 3.83 % 0.00 %

N/A

USD 2.35M
PINK Simplify Exchange Traded .. 3.53 % 0.00 %

N/A

USD 0.12B
DRUG:AU BetaShares Global Healthc.. 3.44 % 0.00 %

N/A

USD 0.16B
CURE Direxion Daily Healthcare.. 3.31 % 1.06 %

N/A

USD 0.19B
XFVT:LSE Xtrackers FTSE Vietnam Sw.. 3.16 % 0.00 %

N/A

USD 0.35B
XVTD:LSE Xtrackers - FTSE Vietnam .. 3.16 % 0.00 %

N/A

USD 0.32B
WELG:XETRA Amundi S&P Global Health .. 3.14 % 0.00 %

N/A

USD 0.24B
WELS:XETRA Amundi S&P Global Health .. 3.14 % 0.00 %

N/A

USD 0.24B
CDNA:CA CI Bio-Revolution ETF 3.03 % 0.00 %

N/A

CAD 4.55M
IXJ iShares Global Healthcare.. 3.00 % 0.46 %

N/A

USD 3.92B
WHEA:LSE SPDR® MSCI World Health .. 2.93 % 0.00 %

N/A

USD 0.56B
HEAW:LSE SPDR® MSCI World Health .. 2.93 % 0.00 %

N/A

USD 0.57B
XDWH:LSE Xtrackers MSCI World Heal.. 2.88 % 0.00 %

N/A

USD 2.42B
XDWH:F Xtrackers (IE) Public Lim.. 2.88 % 0.00 %

N/A

USD 2.60B
XDWH:XETRA Xtrackers MSCI World Heal.. 2.88 % 0.00 %

N/A

USD 2.60B
XWHS:LSE Xtrackers MSCI World Heal.. 2.88 % 0.00 %

N/A

USD 2.47B
WHEA:SW SPDR MSCI World Health Ca.. 2.88 % 0.00 %

N/A

N/A
ABIE:XETRA AXA IM ACT Biodiversity E.. 2.62 % 0.00 %

N/A

N/A
MOAT:LSE VanEck Morningstar US Sus.. 2.61 % 0.00 %

N/A

USD 0.48B
MOGB:LSE VanEck Morningstar US Sus.. 2.60 % 0.00 %

N/A

USD 0.53B
GMVM:XETRA VanEck Morningstar US Sus.. 2.60 % 0.00 %

N/A

USD 0.53B
MOAT:SW VanEck Morningstar US Sus.. 2.51 % 0.00 %

N/A

N/A
ABIT:XETRA AXA IM ACT Biodiversity E.. 2.32 % 0.00 %

N/A

USD 0.40B
ABIT:F AXA IM ACT Biodiversity E.. 2.32 % 0.00 %

N/A

N/A
ABIE:F AXA IM ACT Biodiversity E.. 2.32 % 0.00 %

N/A

N/A
HYLG Global X Funds - Global X.. 1.96 % 0.00 %

N/A

USD 2.85M
XMLH:XETRA L&G Healthcare Breakthrou.. 1.89 % 0.00 %

N/A

USD 0.07B
DOCG:LSE L&G Healthcare Breakthrou.. 1.84 % 0.00 %

N/A

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.84 % 0.00 %

N/A

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 1.78 % 0.00 %

N/A

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.78 % 0.00 %

N/A

USD 0.07B
DFUV Dimensional US Marketwide.. 1.17 % 0.00 %

N/A

USD 10.15B
JPST JPMorgan Ultra-Short Inco.. 0.74 % 0.00 %

N/A

USD 22.73B
CWS AdvisorShares Focused Equ.. 0.00 % 0.68 %

N/A

USD 0.14B
FHLC Fidelity® MSCI Health Ca.. 0.00 % 0.08 %

N/A

USD 2.94B
IBLN 0.00 % 0.64 %

N/A

N/A
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

N/A

USD 3.23B
JHMH 0.00 % 0.46 %

N/A

N/A
LDUR PIMCO Enhanced Low Durati.. 0.00 % 1.02 %

N/A

USD 0.89B
JMIN 0.00 % 0.12 %

N/A

N/A
PSET Principal Quality ETF 0.00 % 0.29 %

N/A

USD 0.05B
LRGE ClearBridge Large Cap Gro.. 0.00 % 0.59 %

N/A

USD 0.22B
ACT Enact Holdings Inc 0.00 % 0.75 %

N/A

USD 4.99B
KORP American Century Diversif.. 0.00 % 0.45 %

N/A

USD 0.24B
BGU:CA Bristol Gate Concentrated.. 0.00 % 0.85 %

N/A

CAD 0.11B
LS:CA Middlefield Healthcare & .. 0.00 % 2.21 %

N/A

CAD 0.16B
HWF:CA 0.00 % 0.00 %

N/A

N/A
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

N/A

USD 0.06B
CGAA:CA CI Global Asset Allocatio.. 0.00 % 0.00 %

N/A

CAD 0.02B
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

N/A

USD 1.11M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD 1.11M
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

N/A

USD 0.09B
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

N/A

USD 16.98B
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

N/A

CAD 0.58B
XLV Health Care Select Sector.. 0.00 % 0.13 %

N/A

USD 37.76B
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.69 %

N/A

CAD 0.01B
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

USD 0.38B
HIG-U:CA 0.00 % 0.00 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A
IXJ:AU iShares Global Healthcare.. 0.00 % 0.00 %

N/A

USD 1.35B
DWEQ 0.00 % 0.00 %

N/A

N/A
BGU-U:CA Bristol Gate Concentrated.. 0.00 % 0.00 %

N/A

CAD 0.11B
PFUT Putnam Sustainable Future.. 0.00 % 0.00 %

N/A

USD 0.23B
SROI Calamos Antetokounmpo Glo.. 0.00 % 0.00 %

N/A

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.07% 86% B+ 78% C+
Dividend Return 0.07% 14% F 2% F
Total Return 8.14% 86% B+ 76% C+
Trailing 12 Months  
Capital Gain 3.37% 67% D+ 48% F
Dividend Return 0.13% 17% F 1% F
Total Return 3.50% 67% D+ 37% F
Trailing 5 Years  
Capital Gain 110.48% 100% F 89% A-
Dividend Return 1.75% 20% F 5% F
Total Return 112.23% 100% F 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 17.59% 92% A 82% B
Dividend Return 17.82% 92% A 81% B-
Total Return 0.23% 33% F 6% D-
Risk Return Profile  
Volatility (Standard Deviation) 23.26% 75% C 49% F
Risk Adjusted Return 76.61% 100% F 93% A
Market Capitalization 56.05B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 37.46 42% 17%
Price/Book Ratio 4.73 46% 19%
Price / Cash Flow Ratio 26.29 31% 10%
Price/Free Cash Flow Ratio 22.37 31% 11%
Management Effectiveness  
Return on Equity 13.09% 54% 68%
Return on Invested Capital 8.92% 57% 61%
Return on Assets 4.72% 54% 70%
Debt to Equity Ratio 67.01% 38% 50%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.